You will be working with a company that has developed a methylation-specific gene-editing platform. You will prioritize epigenetic indications and strategize proof-of-concept programs for the client by conducting primary and secondary research. 

An early-stage product company is developing smart solutions for whole-room health. The company has developed a light that emits in the far-UVC range, which has been shown to kill many pathogens and strongly indicated to be completely harmless to humans. This technology has the potential to revolutionize public health and greatly reduce the transmission of […]

Project timeline: June 20th – August 2022, 6-8 weeks Who you are: A graduate or professional student (i.e. PhD, MD, PharmD, MBA, MS), postdoc, clinical resident, or recent graduate Enthusiastic about gaining life-science business experience and helping a client identify how to have the most patient-health impact with their therapeutic Eager to build teamwork and […]

The multi-institutional project team will perform due diligence on life science and therapeutics startups under consideration by venture capital firms in the Bay Area. For each company, the team may evaluate the following key areas: 1) company capabilities (e.g. scientific merit, intellectual property, etc.), 2) market attractiveness, and 3) competitive landscape. Team members will interact […]

You will be working with a seed-stage biotechnology company planning to commercialize a platform for automating common laboratory protocols.

An early-stage biotechnology company with expertise in antibody therapeutics development is engaging BCBA to explore the GPCR-targeted therapeutics market. To that end, the BCBA project team will 1) conduct a comprehensive market landscape analysis of the GPCR therapeutic market to understand the market conditions and requirements for the development of compelling Proof-of-Concept (POC) programs in […]

You will be working with a company that has developed a revolutionary patient-derived tumor modeling platform for precision diagnostics and next generation oncology drug discovery.